Link to bioRxiv paper: http://medrxiv.org/cgi/content/short/2023.07.31.23293441v1?rss=1 Authors: Li, Y., Choudhary, M. C., Regan, J., Boucau, J., Nathan, A., Speidel, T., Liew, M. Y., Edelstein, G. E., Kawano, Y., Uddin, R., Deo, R., Marino, C., Getz, M. A., Reynold, Z., Barry, M., Gilbert, R. F., Tien, D., Sagar, S., Vyas, T. D., Flynn, J. P., Hammond, S. P., Novack, L. A., Choi, B., Cernadas, M., Wallace, Z. S., Sparks, J. A., Vyas, J. M., Seaman, M. S., Gaiha, G. D., Siedner, M. J., Barczak, A. K., Lemieux, J. E., Li, J. Z. Abstract: Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged SARS-CoV-2 infection, but the immune defects that predispose to persistent COVID-19 remain incompletely understood. In this study, we performed detailed viro-immunologic analyses of a prospective cohort of participants with COVID-19. The median time to nasal viral RNA and culture clearance in the severe hematologic malignancy/transplant group (S-HT) were 72 and 21 days, respectively, which were significantly longer than clearance rates in the severe autoimmune/B-cell deficient (S-A), non-severe, and non-immunocompromised groups (P less than 0.001). Participants who were severely immunocompromised had greater SARS-CoV-2 evolution and higher risk of developing antiviral treatment resistance. Both S-HT and S-A participants had diminished SARS-CoV-2-specific humoral, while only the S-HT group had reduced T cell-mediated responses. This highlights the varied risk of persistent COVID-19 across immunosuppressive conditions and suggests that suppression of both B and T cell responses results in the highest contributing risk of persistent infection. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC